These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438 [TBL] [Abstract][Full Text] [Related]
4. BAFfling pathologies: Alterations of BAF complexes in cancer. Arnaud O; Le Loarer F; Tirode F Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Kim KH; Roberts CW Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101 [TBL] [Abstract][Full Text] [Related]
6. SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia. Chatterjee SS; Biswas M; Boila LD; Banerjee D; Sengupta A Mol Cancer Res; 2018 May; 16(5):791-804. PubMed ID: 29483235 [TBL] [Abstract][Full Text] [Related]
7. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma. Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887 [TBL] [Abstract][Full Text] [Related]
8. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449 [TBL] [Abstract][Full Text] [Related]
9. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas. Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482 [TBL] [Abstract][Full Text] [Related]
10. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797 [TBL] [Abstract][Full Text] [Related]
11. Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler. Woodley CM; Romer AS; Wang J; Guarnaccia AD; Elion DL; Maxwell JN; Guerrazzi K; McCann TS; Popay TM; Matlock BK; Flaherty DK; Lorey SL; Liu Q; Tansey WP; Weissmiller AM Oncogene; 2021 May; 40(20):3593-3609. PubMed ID: 33931740 [TBL] [Abstract][Full Text] [Related]
12. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315 [TBL] [Abstract][Full Text] [Related]
13. Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling. Valencia AM; Collings CK; Dao HT; St Pierre R; Cheng YC; Huang J; Sun ZY; Seo HS; Mashtalir N; Comstock DE; Bolonduro O; Vangos NE; Yeoh ZC; Dornon MK; Hermawan C; Barrett L; Dhe-Paganon S; Woolf CJ; Muir TW; Kadoch C Cell; 2019 Nov; 179(6):1342-1356.e23. PubMed ID: 31759698 [TBL] [Abstract][Full Text] [Related]
14. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Wang X; Haswell JR; Roberts CW Clin Cancer Res; 2014 Jan; 20(1):21-7. PubMed ID: 24122795 [TBL] [Abstract][Full Text] [Related]
15. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors. Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303 [TBL] [Abstract][Full Text] [Related]
16. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. Sasaki M; Kato D; Murakami K; Yoshida H; Takase S; Otsubo T; Ogiwara H Nat Commun; 2024 Jun; 15(1):4770. PubMed ID: 38839769 [TBL] [Abstract][Full Text] [Related]
17. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2. Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623 [TBL] [Abstract][Full Text] [Related]